HDA Media And Political Bulletin – 13 January 2016

Funding cuts equivalent to 12% ‘net’ loss over 6 months

C&D, Samuel Horti, 11 January 2016

The Government confirmed that the announced funding cuts would fall between October 2016 and March 2017, which amounts to a net funding fall by 12%. Accountant Umesh Modi explains that pharmacists will be overpaid in the first 6 months, before the capital is “clawed back”.


ABPI response to publication of the latest figures on the uptake and use of NICE approved medicines in the NHS in England

ABPI, Press Office, 12 January 2016

Alison Clough, ABPI’s acting CEO, responds to the publication of the NICE Technology Appraisals in the NHS in England – Innovation Scorecard. The ABPI calls out the variations in access to modern medicines highlighted by the Scorecard. It will investigate the causes of this variation and cooperate with the appropriate bodies to overcome these barriers.


January NCSO/Price Concessions

PSNC, 12 January 2016

The Department of Health granted the following price concessions for January 2016:

The price concession only applies to the month that it is granted.

No additional endorsements are required for price concessions.

Drug Pack size Price concession
Celiprolol 200mg tablets 28 £19.83
Celiprolol 400mg tablets 28 £39.65
Cimetidine 400mg tablets 60 £10.30
Clindamycin 150mg capsules 24 £11.80
Ferrous Sulfate 200mg tablets 28 £2.85
Flecanide 50mg tablets 60 £5.05
Flecanide 1000mg tablets 60 £5.29
Lamotrigine 5mg dispersible tablets sugar free 28 £8.50
Lercanidipine 10mg tablets 28 £5.70
Mefenamic acid 500mg tablets 28 £10.80
Nefopam 30mg tablets 90 £35.00
Pioglitazone 15mg tablets 28 £25.83
Pioglitazone 45mg tablets 28 £39.55
Procyclidine 5mg tablets 28 £14.00
Trazodone 50mg/5ml oral solution sugar free 120ml £140.00
Trazodone 100mg capsules 56 £28.14


If you have problems obtaining a Part VIII product or problems obtaining the product at the set Drug Tariff price, please report the issue to PSNC using the online feedback form on the PSNC Website. If you have been able to source the product, please provide full details of the supplier and price paid.

PSNC will investigate the extent of the problem and if appropriate discuss the issue with the Department of Health. Please note that PSNC cannot provide details of generic products that are suspected of being affected by generic supply problems unless and until the Department of Health grants a concession. PSNC is in discussion with the Department of Health on a number of generic medicines in short supply.


Parliamentary Coverage


There is no Parliamentary coverage today.


Full Coverage

ABPI response to publication of the latest figures on the uptake and use of NICE approved medicines in the NHS in England

ABPI, Press Office, 12 January 2016

The figures, published today [Tuesday, 12 January] are from latest publication of the NICE Technology Appraisals in the NHS in England – Innovation Scorecard. Published by the Health and Social Care Information Centre (HSCIC), the Scorecard pulls together existing local data from across the NHS to show the regional provision of NICE-approved medicines and technologies.

Click here to view the Scorecard data.​

ABPI’s acting CEO, Alison Clough, said:

“We are not surprised to see that today’s figures show that access to modern medicines to treat and prevent a wide range of diseases, including cancer and diabetes, is still subject to wide variation across England. In some cases we are seeing variation of 30 fold in access to GP or hospital prescribed medicines – for example for newer stroke prevention medicines – all of which are approved by NICE as being clinically and cost effective and should therefore be widely and routinely available.

Without further detail and analysis of the figures it is difficult to know why we are seeing such wide variation in patient access to newer medicines. The ability to access potentially life-saving or life-enhancing medication shouldn’t be dependent solely on cost or geography and it would be disappointing if this was the case in some areas. The ABPI will be carrying out an immediate investigation into today’s figures and we will be working with the appropriate bodies – NHS, patient groups and charities – to try and address issues of inequality of access for those patients who, for whatever reason, are missing out on the most appropriate medicines for their care.

The ABPI is completely supportive of the Scorecard to measure the uptake of new medicines and drive innovation. For the scheme to be a success we – and all of the organisations involved – must begin to address the reasons for the persistently low levels of medicines access that we believe the Scorecard is highlighting and take action.

In order to achieve this the Scorecard needs to be more widely understood so that it can be used at local planning level by the NHS. For this to happen it is vital that the scorecard be launched in a more user friendly and easy to understand format.”

HDA Media And Political Bulletin – 13 January 2016

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?